Skip to main content
. 2021 May 24;21:597. doi: 10.1186/s12885-021-08306-5

Table 2.

Results of Cost-effectiveness Analysis

Strategy Cost Incremental Cost Un adjusted Life-years Incremental LYs QALYs Incremental QALYs ICER ($/QALY)
SSA $606,397 $170,455 4.41 0.62a 2.90 0.44 $388,966
Delay SSA $435,942 3.78 2.46

aNumbers do not sum because of rounding

SSA somatostatin analogues; LY life years; QALYs quality-adjusted life years; ICER incremental cost-effectiveness ratio